2. Academic Validation
  3. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3

The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3

  • Bioorg Med Chem. 2016 Nov 1;24(21):5036-5046. doi: 10.1016/j.bmc.2016.08.008.
Sun-Mi Lee 1,  Kyoung Bin Yoon 2,  Hyo Jeong Lee 2,  Jiwon Kim 3,  You Kyoung Chung 4,  Won-Jea Cho 5,  Chisato Mukai 6,  Sun Choi 4,  Keon Wook Kang 3,  Sun-Young Han 7,  Hyojin Ko 8,  Yong-Chul Kim 9
Affiliations

Affiliations

  • 1 Department of Medical System Engineering, Gwangju Institute of Science and Technology (GIST), 123 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea.
  • 2 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.
  • 3 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
  • 4 National Leading Research Laboratory (NLRL) of Molecular Modeling & Drug Design, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
  • 5 College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea.
  • 6 School of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
  • 7 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea. Electronic address: syhan@gnu.ac.kr.
  • 8 School of Life Science, Gwangju Institute of Science and Technology (GIST), Republic of Korea. Electronic address: kohyojin@gist.ac.kr.
  • 9 Department of Medical System Engineering, Gwangju Institute of Science and Technology (GIST), 123 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea; School of Life Science, Gwangju Institute of Science and Technology (GIST), Republic of Korea. Electronic address: yongchul@gist.ac.kr.
PMID: 27555284 DOI: 10.1016/j.bmc.2016.08.008
Abstract

Members of the Janus kinase (JAK) family are potential therapeutic targets. Abnormal signaling by mutant JAK2 is related to hematological malignancy, such as myeloproliferative neoplasms (MPNs), and tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung Cancer (NSCLC). We discovered a potent and highly selective inhibitor of JAK2 over JAK1 and -3 based on the structure of 4-(2,5-triazole)-pyrrolopyrimidine. Among all triazole compounds tested, 2,5-triazole regioisomers more effectively inhibited JAK2 kinase activity than isomers with substitutions of various alkyl groups at the R2 position, except for methyl-substituted 1,5-triazole, which was more potent than the corresponding 1,4- and 2,5-triazoles. None of the synthesized 1,4-isomers inhibited all three JAK family members. Compounds with phenyl or tolyl group substituents at the R1 position were completely inactive compared with the corresponding analogues with a methyl substituted at the R1 position. As a result of this structure-activity relationship, 54, which is substituted with a cyclopropylmethyl moiety, exhibited significant inhibitory activity and selectivity (IC50=41.9nM, fold selectivity JAK1/2 10.6 and JAK3/2 58.1). Compound 54 also exhibited an equivalent inhibition of wild type JAK2 and the V617F mutant. Moreover, 54 inhibited the proliferation of HEL 92.1.7 cells, which carry JAK2 V617F, and gefitinib-resistant HCC827 cells. Compound 54 also suppressed STAT3 phosphorylation at Y705.

Keywords

4-(2,5-Triazole)-pyrrolopyrimidine; JAK2; JAK2 inhibitor; JAK2V617F; STAT (signal transducer and activator of transcription).

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z